Senescence is frequently triggered in tumours in response to chemotherapy and radiotherapy treatment in cancer patients [59, 60] and it has been demonstrated that PTEN-loss-induced cellular senescence inhibits tumorigenesis in vivo in a human xenograft model of prostate cancer [61]. The gene discussed is PTEN; the disease is prostate cancer.